Pangaea Oncology, S.A. (PANG.MC)
MCE · EUR · Healthcare · Diagnostics & Research
€1.47 (+0.00%) as of
Key statistics
- Market cap
- 52.79M
- Forward P/E
- ∞
- EPS (TTM)
- -0.1100
- Dividend yield
- 0.00%
- 52-week range
- 1.4300 – 1.7500
- Beta
- 0.03
- Revenue (TTM)
- 14.52M
- Profit margin
- -24.76%
- Volume
- 8.80k
About Pangaea Oncology, S.A.
Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling and transcriptomic signatures; and tumor mutational burden (TMB) and microsatellite instability and (MSI) assessment services. It also provides diagnostic platforms validation and pre-clinical services. Pangaea Oncology, S.A. was incorporated in 2006 and is based in Zaragoza, Spain.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Zaragoza, Spain
- Employees
- 165
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.